A Study on Scalp Health and Integrated Scalp Management Protocols for Hair Transplant Patients

Inclusion Criteria: 1. Healthy Chinese male subjects aged between 18 and 55 years old; 2. Diagnosed with androgenetic alopecia, with alopecia grade from Grade II to Grade VI per Hamilton-Norwood classification; 3. Scheduled to receive hair transplantation; scalp condition is confirmed suitable for trial participation by dermatologist assessment after hair graft surgery; 4. With or without mild-to-moderate scalp seborrheic dermatitis (SD score ranging from 0 to 9); 5. No anti-dandruff shampoo used within the latest 14 days prior to enrollment; 6. No hair dyeing, perming or hair styling cosmetic treatments in the past 30 days; 7. Able to comply with all scheduled study visits; 8. Possess normal communication and comprehension capacity; 9. Agree to regular follow-up visits and complete related questionnaires on time; 10. Fully understand trial procedures, volunteer to join the study and provide written informed consent. Exclusion Criteria: 1. Suffering from severe scalp seborrheic dermatitis; 2. Received oral or topical antifungal drugs, glucocorticoids or other therapeutic medicines for seborrheic dermatitis within the preceding 30 days; 3. Complicated with other scalp diseases (such as psoriasis), or with obvious infection or unhealed wounds on the target treatment area; 4. Known hypersensitivity to ingredients including selenium disulfide, salicylic acid and related components; 5. History of autoimmune diseases or severe organic diseases involving heart, brain, lung, liver, kidney and other vital organs; 6. Past medical history of psychiatric or psychological disorders; 7. Refuse to sign the written informed consent form; 8. Currently enrolled in another interventional clinical trial; 9. Diagnosed with alopecia areata, pseudopelade, cicatricial alopecia or other scalp and hair disorders; 10. Have taken part in any other clinical trial within the prior 3 months; 11. Judged as inappropriate for trial participation based on investigator's clinical assessment.